• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    9/28/21 4:31:04 PM ET
    $SRNG
    Get the next $SRNG alert in real time by email
    SC 13G 1 d146836dsc13g.htm SC 13G SC 13G

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.    )*

     

     

    Ginkgo Bioworks Holdings, Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    37611X100

    (CUSIP Number)

    September 16, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 37611X100    Schedule 13G    Page 1 of 5

     

      1    

      Names of Reporting Persons

     

      Thomas Knight

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         5     

      Sole Voting Power

     

      9,219,119

         6   

      Shared Voting Power

     

      65,963,933

         7   

      Sole Dispositive Power

     

      9,219,119

        8   

      Shared Dispositive Power

     

      65,963,933

     9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      75,183,052

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      5.6%

    12  

      Type of Reporting Person

     

      IN


    CUSIP No. 37611X100    Schedule 13G    Page 2 of 5

     

    ITEM 1.

    (a) Name of Issuer:

    Ginkgo Bioworks Holdings, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    27 Drydock Avenue, 8th Floor, Boston, MA 02210.

     

    ITEM 2.

    (a) Name of Person Filing:

    Thomas Knight (the “Reporting Person”).

     

      (b)

    Address or Principal Business Office:

    The business address of the Reporting Person is c/o Ginkgo Bioworks Holdings, Inc., 27 Drydock Avenue, 8th Floor, Boston, MA 02210.

     

      (c)

    Citizenship of each Reporting Person is:

    The Reporting Person is a citizen of the United States.

     

      (d)

    Title of Class of Securities:

    Class A common stock, par value $0.0001 per share (“Class A Common Stock”).

     

      (e)

    CUSIP Number:

    37611X100    

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of September 16, 2021, based upon 1,330,072,374 shares of Class A Common Stock outstanding.

     

      •  

    Amount beneficially owned: 75,183,052

     

      •  

    Percent of Class: 5.6%

     

      •  

    Number of shares the Reporting Person has:


    CUSIP No. 37611X100    Schedule 13G    Page 3 of 5

     

      •  

    Sole power to vote or direct the vote: 9,219,119

     

      •  

    Shared power to vote: 65,963,933

     

      •  

    Sole power to dispose or direct the disposition of: 9,219,119

     

      •  

    Shared power to dispose or direct the disposition of: 65,963,933

    The share amount reported herein consists of (i) 9,219,119 shares of Class B common stock, $0.0001 per share, of the Issuer (the “Class B Common Stock”) held of record by the Reporting Person; (ii) 6,995,255 shares of Class A Common Stock held of record by the Knight Family Trust dated August 20, 2019; (iii) 49,976,145 shares of Class A Common Stock held of record by the Thomas F. Knight, Jr., Trustee of The Thomas F. Knight Jr. Grantor Retained Annuity Trust or his/her successor in trust; and (iv) 8,992,533 shares of Class A Common Stock held of record by the Thomas F. Knight Jr. Grantor Retained Annuity Trust (2) dated December 16, 2020. The Reporting Person serves as co-trustee for the Thomas F. Knight, Jr., Trustee of The Thomas F. Knight Jr. Grantor Retained Annuity Trust or his/her successor in trust and the Thomas F. Knight Jr. Grantor Retained Annuity Trust (2) dated December 16, 2020, and the Reporting Person’s spouse serves as co-trustee for the Knight Family Trust dated August 20, 2019. As such, the Reporting Person may be deemed to share beneficial ownership over the shares held of record by each of the trusts.

    The shares of Class B Common Stock may be redeemed by the holder at any time for shares of Class A Common Stock on a one-to-one basis. 8,055,129 of the reported shares constitute earn-out shares subject to forfeiture, which vest in four substantially equal installments if the Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00.

    ITEM 5. Ownership of Five Percent or Less of a Class.

    Not applicable.

    ITEM 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable.

    ITEM 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

    ITEM 8. Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 37611X100    Schedule 13G    Page 4 of 5

     

    ITEM 9. Notice of Dissolution of Group.

    Not applicable.

    ITEM 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 37611X100    Schedule 13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: September 27, 2021

     

    By:

     

    /s/ Thomas Knight

    Name:

     

    Thomas Knight

    Get the next $SRNG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRNG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds

    Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021 Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021 $1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction. Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors. Business combination with Ginkgo approved by Soaring Eagl

    9/14/21 9:13:00 AM ET
    $SRNG

    Africa CDC and Ginkgo Bioworks Announce Collaboration to Strengthen Laboratory Network Capacity Across African Union Member States

    BOSTON and ADDIS ABABA, Ethiopia, Sept. 14, 2021 /PRNewswire/ -- The Africa Centres for Disease Control and Prevention (Africa CDC), a specialized technical institution of the African Union, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to bolster the laboratory network capacity for African Union Member States. The partnership is aimed at supporting the continent's public health institutions with appropriate tools, training, and data infrastructure to leverage critical genomic sequencing technologies that will be implemented through Africa CDC Institute for Pathogen Genomics (IPG) and Ginkgo Bioworks.  Gin

    9/14/21 7:58:00 AM ET
    $SRNG

    Concentric by Ginkgo Stands Ready to Continue Fighting Pandemic, Providing Biosecurity and COVID Testing Nationwide to Schools, Workplaces, and Other Congregate Settings

    BOSTON, Sept. 10, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced its readiness to continue scaling support for COVID testing in congregate settings in response to new emergency standards and recommendations issued by the Biden-Harris Administration. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Last year, Ginkgo launched Concentric by Ginkgo, its public health and biosecurity initiative, to provide a response to the COVID-19 pandemic. Since then, Conc

    9/10/21 3:00:00 PM ET
    $SRNG

    $SRNG
    SEC Filings

    View All

    SEC Form EFFECT filed by Soaring Eagle Acquisition Corp.

    EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/21/21 12:15:16 AM ET
    $SRNG

    SEC Form 424B3 filed by Soaring Eagle Acquisition Corp.

    424B3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/20/21 5:24:23 PM ET
    $SRNG

    Soaring Eagle Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

    8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/20/21 5:19:07 PM ET
    $SRNG

    $SRNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Cascade Investment, L.L.C. claimed ownership of 151,865,481 units of Class A Common Stock

    3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/24/21 4:24:22 PM ET
    $SRNG

    SEC Form 3: New insider Viking Global Investors Lp claimed ownership of 339,055,144 units of Class A Common Stock

    3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/23/21 4:11:12 PM ET
    $SRNG

    SEC Form 4: Eagle Equity Partners Iii, Llc returned 11,534,052 units of Class A Common Stock to the company, decreasing direct ownership by 27% to 31,590,948 units

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/22/21 9:57:03 PM ET
    $SRNG

    $SRNG
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Announces Date of First Half 2021 Results Presentation

    BOSTON, Aug. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo"), which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET. The presentation will include an overview of first half performance, recent updates, and a discussion on Ginkgo's business model and outlook. The presentation details and registration link will be available on Ginkgo's investor relation

    8/9/21 7:00:00 AM ET
    $SRNG

    $SRNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Soaring Eagle Acquisition Corp. (Amendment)

    SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    10/1/21 5:02:37 PM ET
    $SRNG

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/28/21 4:31:04 PM ET
    $SRNG

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/27/21 5:29:26 PM ET
    $SRNG